title: Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists.
abstract: Ulcerative colitis can cause debilitating symptoms and complications such as colonic strictures, colonic dysplasia, colorectal cancer, and toxic megacolon or perforation. Goals of treatment in ulcerative colitis include resolution of gastrointestinal symptoms, healing of colonic mucosa, and prevention of disease complications. Our treatment armamentarium has expanded dramatically over the past 10 years, and we now have multiple biologic agents approved for the treatment of moderate-severe disease, in addition to conventional therapies such as 5-aminosalicylates, thiopurines, and corticosteroids. In this review, we will provide a detailed discussion of the three tumor necrosis factor-alpha (TNF-α) inhibitors currently approved for treatment of ulcerative colitis: infliximab, adalimumab, and golimumab. All three agents are effective for inducing and maintaining clinical response and remission in patients with ulcerative colitis, and they have comparable safety profiles. There are no head-to-head trials comparing their efficacy, and the choice of agent is most often based on insurance coverage, route of administration, and patient preference. Combination therapy with an immunomodulator is proven to be more effective than anti-TNF monotherapy, and patients who lose response to an anti-TNF agent should undergo dose intensification in order to regain clinical response. Despite therapeutic optimization, a significant percentage of patients will not achieve clinical remission with anti-TNF agents, and so newer therapies are on the horizon.
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, WA, USA.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Fausel
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, WA, USA ; Inflammatory Bowel Disease Program, UW Medicine - Harborview Medical Center, Seattle, WA, USA.
authors.forename: Anita
authors.initials: A
authors.lastname: Afzali
keywords: adalimumab; golimumab; inflammatory bowel disease; infliximab; ulcerative colitis